Day: March 24, 2023

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Written by Customer Service on March 24, 2023. Posted in Earnings Releases And Operating Results.

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company’s progress. “2022 represented an extremely active year at Vaccitech in which the company continued to advance its exciting pipeline and strengthen the infrastructure necessary to support this and future growth. We announced the completion of enrollment of three clinical trials, and initiated dosing in three new trials. This, combined with the announcement of new, state-of-the-art laboratories and offices in the US and the UK, and...

Jushi Holdings Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

Written by Customer Service on March 24, 2023. Posted in Public Companies.

BOCA RATON, Fla., March 24, 2023 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the fourth quarter and full year ended December 31, 2022, before the market opens on Friday, March 31, 2023. Management will host a conference call and audio webcast on Friday, March 31, 2023, at 8:00 a.m. ET to discuss the Company’s financial results.Event: Fourth Quarter and Full Year 2022 Financial Results Conference CallDate: Friday, March 31, 2023Time: 8:00 a.m. Eastern TimeLive Call: 1-800-715-9871 (U.S. & Canada Toll-Free)Conference ID 6955959Webcast: RegisterFor interested individuals unable to join the conference call, a webcast of the call will be available...

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Written by Customer Service on March 24, 2023. Posted in Earnings Releases And Operating Results.

Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicines On track to submit IND for ONCR-021 in mid-2023 Preclinical data featured in Nature Communications support self-amplifying RNA platform and promise of repeat IV-administration Ended the quarter with $62.2 million in cash, cash equivalents and investments to support next-generation RNA therapeutics pipelineANDOVER, Mass., March 24, 2023 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported fourth quarter and full year 2022 financial results and provided an update on its business. “We are poised for a year of strong execution as we head further into 2023. Oncorus is pioneering a first-of-its-kind,...

Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

Written by Customer Service on March 24, 2023. Posted in Earnings Releases And Operating Results.

— Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., March 24, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate accomplishments. “During 2022, we continued to make significant progress...

Grace Breeding Reports 2022 Full-Year Financial Results

Written by Customer Service on March 24, 2023. Posted in Earnings Releases And Operating Results.

– Program developments throughout 2022, and, to date in 2023, bring Grace Breeding closer to offering crop solutions to farmers aligned with environmental responsibility and reversing climate change – REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) — Grace Breeding Ltd. (the “Company” or “Grace Breeding”) (TASE: GRAC), a forward-thinking AgClimateTech company developing biological-based products to improve crop yield and vigor today reported full-year financial results for the period ending December 31, 2022. “In 2022 just after taking the company public, and so far in 2023, we have made great strides to advance our NFT and WDS programs in parallel, bringing us closer towards our goal to sustainably address upstream and downstream solutions for the crop life cycle,” stated Assaf Dotan, Chief...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 24, 2023. Posted in Earnings Releases And Operating Results.

TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023 Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024 Expected cash runway extended through at least the second quarter of 2024 with recent $20 million in financing, with potential to receive up an additional $80 millionSAN MATEO, Calif. and SINGAPORE, March 24, 2023 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities. “We...

Irwin Naturals Cannabis Products Launch Nationwide in Canada

Written by Customer Service on March 24, 2023. Posted in Public Companies.

Company announces products being available nationwide through Starseed Medicinal Medical PlatformIrwin Naturals Cannabis 25mg CBD Softgel Irwin Naturals Cannabis 25mg CBD SoftgelLOS ANGELES, March 24, 2023 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), is proud to announce the release of Irwin Naturals Cannabis’ new CBD 25mg Softgels in Canada, available nationwide through the Starseed Medicinal Medical Group platform. CBD 25mg Softgels are just the first of five CBD and THC products that Irwin Naturals Cannabis, through its licensing agreement with Entourage Health Corp., plans to launch nationwide in Canada over the next few months. The company’s product lineup will include a range of CBD and THC products designed in a variety of formulations to suit consumers’...

Abeona Therapeutics Announces New Employee Inducement Grants

Written by Customer Service on March 24, 2023. Posted in Public Companies.

NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, Abeona granted restricted stock equity awards to six employees as an inducement for them to accept employment, which equity awards relate to, in the aggregate, up to 131,750 restricted shares of Abeona common stock. One-quarter (1/4) of the shares subject to such restricted stock awards vesting on the first anniversary of the grant date, conditioned upon each employee’s continued employment on the vesting date(s). The inducement grants were approved by Abeona’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule...

Global Crossing Airlines Announces Agreement with CubaMax for up to nine flights per week to Cuba with growth of up to 23 flights per week

Written by Customer Service on March 24, 2023. Posted in Public Companies.

MIAMI, March 24, 2023 (GLOBE NEWSWIRE) — Global Crossing Airlines Group, Inc. (JET: NEO; JET.B: NEO; JETMF: OTCQB) (the “Company” or “GlobalX”) is pleased to announce that is has signed a long term agreement with CubaMax Travel (“CubaMax”), one of the leading OFAC approved tour operators, to initially provide air service to two (2) cities in Cuba, with nine (9) flights per week total to Havana and Santa Clara, Cuba. This is projected to grow to 23 flights per week to 5 cities in Cuba within the next six months. The contract will initially provide revenues to GlobalX of up to $12 million per year and will start April 1, 2023. Once the additional fights are added, GlobalX expects to generate revenues of over $30 million per year on this contract. “We are very pleased to be working with CubaMax, one of the largest tour operators to...

CRYPTYDE PROVIDES OPERATIONAL AND BUSINESS UPDATE ON ITS SUBSIDIARY, FOREVER 8

Written by Customer Service on March 24, 2023. Posted in Public Companies.

SAFETY HARBOR, Florida, March 24, 2023 (GLOBE NEWSWIRE) — Cryptyde, Inc. (NASDAQ: TYDE) is pleased to provide its investors a corporate update on its subsidiary, Forever 8 Fund, LLC (“Forever 8” or “F8”). The company continues to strengthen its operational and technological performance. Highlights: Technology As F8 begins to scale its customer count, it continues to invest in both its customer facing and internal portfolio and customer management technologies. During the last 6 months, F8 has rolled out proprietary features that enhance its customers’ inventory management experience. Some of these features include giving customers the ability to leverage F8’s demand forecasting algorithms to optimize their inventory levels and streamline the purchase order process. At the same time, F8 also provides tracking of supply chain data...

Day: March 24, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice